Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C

NCT01577758 | Completed Phase 1 Results

• 3 other identifiers: C260012011-002260-24U1111-1163-9720
• Study Type: interventional
• Target: 41
• Locations: 1 country
• Sites: 1

Brief Summary

This is an Open-Label, Multicenter, Dose Escalation, First-in-Human Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C.

Conditions

Advanced Gastrointestinal Malignancies

Keywords

Phase 1,; Advanced gastrointestinal malignancies,; MLN0264,; Guanylyl Cyclase C(GCC),; Antibody Drug Conjugate(ADC)

Outcome Measures

Primary Outcomes (7)

• Number of Participants With Dose-Limiting Toxicities (DLTs)

  DLT was defined as any of the following Adverse Events (AEs) that occur and are considered by the investigator to be related to therapy. 1. Grade 4 neutropenia (Absolute Neutrophil Count \< 500 cells/mm\^3). 2. Grade 3 or greater neutropenia with fever and/or infection. 3. Grade 4 thrombocytopenia (platelets \< 25,000/mm\^3). 4. Grade 3 or greater thrombocytopenia with clinically meaningful bleeding at any time. 5. Grade 3 or greater nausea and/or emesis that occurs despite of prophylaxis. 6. Grade 3 or greater diarrhea that occurs despite supportive care. 7. Any other Grade 3 or greater non-hematological toxicity other than Grade 3 fatigue or Grade 3 Alopecia. 8. Inability to start the next cycle of therapy due to treatment delay of more than 2 weeks because of lack of recovery. 9. Other MLN0264-related non-hematologic toxicities Grade 2 or greater requiring discontinuation of therapy.

  From the time informed consent is signed through 30 days after the last dose of study drug, approximately 9 months

• Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events

  An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A Serious Adverse Event (SAE) was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

  From the time informed consent is signed through 30 days after the last dose of study drug, approximately 9 months

• Maximum Tolerated Dose (MTD) of MLN0264

  MTD of MLN0264 was determined. Decisions regarding dose escalation were made based on any DLT that occurred during the first cycle of treatment.

  Every 3 weeks until MTD is established, approximately 9 months

• Cmax: Maximum Observed Serum Concentration for MLN0264

  Maximum observed serum concentration (Cmax) is the peak serum concentration of a drug after administration, obtained directly from the serum concentration-time curve. Cmax is reported for the 1.8 mg/kg dose, which is the MTD, where there is adequate data to provide robust parameter information reliably.

  Cycle 1: Day 1 pre-dose to Day 21 post-dose

• Cmax: Maximum Observed Plasma Concentration for Monomethyl Auristatin E (MMAE)

  Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Cmax is reported for the 1.8 mg/kg dose, which is the MTD, where there is adequate data to provide robust parameter information reliably.

  Cycle 1: Day 1 pre-dose to Day 21 post-dose

• AUC0-21 Days: Area Under the Curve Day 0 to Day 21 for MLN0246

  Area under the drug concentration versus time curve from time 0 to Day 21. AUC0-21 is reported for the 1.8 mg/kg dose (the MTD), where there is adequate data to provide robust parameter information reliably.

  Cycle 1: Day 1 pre-dose to 21 Days post-dose

• AUC0-21 Days: Area Under the Curve Day 0 to Day 21 for MMAE

  Area under the plasma drug concentration versus time curve from time 0 to Day 21. AUC0-21 is reported for the 1.8 mg/kg dose (the MTD), where there is adequate data to provide robust parameter information reliably.

  Cycle 1: Day 1 pre-dose to 21 Days post-dose

Secondary Outcomes (2)

• Best Overall Response

  At the completion of every second cycle up to 12 cycles (approximately 9 months). Each cycle is a 21 days cycle

• Number of Participants With Antitherapeutic Antibodies (ATA)

  Day 1 of every 21 days cycle and at End of study (EOS) approximately 9 months

Study Arms (1)

MLN0264

EXPERIMENTAL

MLN0264 starting dose 0.3 mg/kg escalated until Maximum Tolerated Dose (MTD) was determined, 30-minute infusion, on Day 1 of each 21-Day treatment cycle.

Drug: MLN0264

Interventions

MLN0264 DRUG

MLN0264 30-minute infusion on Day 1 of each treatment cycle

MLN0264

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntary consent form
• Diagnosis of GI malignancy with a GCC protein expressing tumor
• Male or female patients 18 years or older with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
• Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to abstain from heterosexual intercourse
• Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate bone marrow, hepatic and renal function as specified in the protocol

You may not qualify if:

• Female patients who are lactating or have a positive serum pregnancy test during the screening period
• Any serious medical or psychiatric illness that could interfere with the completion of treatment
• Major surgery or treatment with investigational drug before the first dose
• Serious infection within 14 days before the first dose of study drug
• Known HIV, inflammatory bowel disease, viral hepatitis or cerebral/meningeal brain metastases
• Patients with cardiovascular conditions specified in protocols
• Patients with history of another primary malignancy not in remission for at least 3 years
• Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.

Sponsors & Collaborators

• Millennium Pharmaceuticals, Inc.: lead

Study Sites (1)

Moffitt Cancer Center

Tampa, Florida, 33612, United States

Location

MeSH Terms

Interventions

indusatumab

Results Point of Contact

• Title: Medical Director, Clinical Science
• Organization: Takeda

clinicaltrialregistry@tpna.com

+1-877-825-3327

Study Officials

• Medical Monitor

  Millennium Pharmaceuticals, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 2, 2012
• First Posted: April 16, 2012
• Study Start: June 1, 2012
• Primary Completion: February 1, 2014
• Study Completion: February 1, 2014
• Last Updated: September 7, 2016
• Results First Posted: July 25, 2016

Record last verified: 2016-09

Locations

US (1)